Pharma Sales

Why did Emcure Pharma share price rise 2% in overall muted market?

At 9:25 AM, Emcure Pharma share price continued to trade 1 per cent higher at ₹1,392, even as BSE Sensex trade flat with a negative bias at 85,509.78 levels.

'Eye on $500 bn by 2047, pharma steps into 2026 with focus on innovation'

India's pharmaceutical industry is stepping into 2026, marking the beginning of a critical five-year period to build the required ecosystem to establish itself as an innovation hub in its bid to become a USD 500 billion sector by 2047, amid near-term challenges of tariff fluctuations and global trade realignments. The predominantly generic medicines-driven domestic drug industry, which has grown from USD 3 billion to USD 60 billion in size over the past 25 years, is shifting towards innovation in next-generation drugs. At the same time, it will also seek to capitalise on the opportunity to capture drugs worth over USD 300 billion that are set to lose exclusivity over the next seven years. "Today, Indian pharma stands at a defining moment and the next 25 years will be shaped by innovation, quality, and access," Indian Pharmaceutical Alliance Secretary General Sudarshan Jain said. The innovation agenda has gained notable momentum among the domestic players, he noted. "From 2026 onwa

Why did Sudeep Pharma plunge 6% in trade today? Key details inside

Sudeep Pharma share price fell on reporting a weak set of results in the September quarter of financial year 2026 (Q2FY26).

Sharekhan upgrades Divi's Labs to 'Buy' on strong FY26-28 growth visibility

The brokerage said Divis Laboratories is entering a stronger growth phase, supported by a robust H2FY26 pipeline and visibility for scale-up over the next two years.

Neuland, Lupin, Divi's lead domestic, CDMO surge amid US generics headwinds

Analysts noted that while US generics face margin headwinds, domestic formulations and CDMOs remain resilient. Biosimilars are also poised for growth through new launches and regulatory support.

Nomura lifts Lupin target price on US momentum, India growth recovery

However, on the bourses, Lupin shares were trading 0.70 per cent lower at ₹1,973.50 per share at 9:30 AM. In comparison, BSE Sensex was trading 0.23 per cent lower at 83,346.45 levels.

Zydus Life Q2: Solid beat on bottom line, analysts mixed on growth outlook

Zydus Life Q2 results review: Foreign brokerage Nomura said Zydus Life delivered results above estimates, led by a stronger-than-expected performance in India.

Brokerages see near-term upside in Dr Reddy's on Semaglutide, ex-US growth

Dr Reddy's Laboratories reported a consolidated Q2FY26 net profit of ₹1,437.2 crore, up 14 per cent Y-o-Y from ₹1,255.3 crore, with sequential growth largely flat.

Nuvama retains 'Hold' on Cipla, raises target after Eli Lilly diabetes deal

Cipla- Eli Lilly deal: Tirzepatide is a prescription drug used for managing type 2 diabetes and aiding weight loss in adults who are obese or overweight.

Nifty Pharma down 2.5% as Trump slaps 100% import tariffs; impact decoded

Among individual counters, Sun Pharma slumped 4.87 per cent to a fresh 52-week low of ₹1,548, while Gland Pharma tumbled 4.70 per cent to ₹1,880. Biocon declined 3.68 per cent to ₹342.85.

Why Nomura continues to back Glenmark Pharma; Retains 'Buy'; Find out here

Analysts at Nomura continue to back Glenmark Pharma, citing the company's ability to strategically acquire high-potential innovative products.

Sun Pharmaceutical: Domestic, innovation push eyed; Nuvama maintains 'Hold'

Sun Pharma aims to strengthen its domestic formulations business through field force expansion and a generic GLP-1 launch in CY26.

Shilpa Medicare hits 5% upper circuit; here's what sparked the rally today

Around 1:30 PM, Shilpa Medicare shares continued to trade 2.04 per cent higher at ₹833.95 per share. In comparison, BSE Sensex was trading flat at 82,176.17 levels.

Pharma in bitter health: Stocks sink upto 38% in 2025; time to bottom fish?

Among stocks, Natco Pharma plunged 37.85%, Ipca Labs 22.43%, Aurobindo Pharma 17.99%, and Sun Pharma 14.30%. Other laggards include Lupin (13.25%), and Dr Reddy's (5.17%).

Here's why Marksans Pharma share was buzzing in trade on March 20

The products will be manufactured at the Verna, Goa facility, and will be marketed & distributed in Australian markets through the Marksans Pharma's subsidiary Nova Pharmaceuticals Australasia Pty

Here's why Zydus Lifesciences share price popped 3% in trade on March 19

The rise in the Zydus Lifesciences shares came after the company received final approval from the United States Food and Drug Administration (USFDA) to manufacture Apalutamide Tablets, 60 mg

NPPA fixes retail prices of 53 drug formulations, including painkillers

The regulatory body, which comes under the Department of Pharmaceuticals (DoP), took the decision to revise the prices of the formulations during the authority's 130th meeting on February 25

Have 5-6 portfolio firms planning IPOs: ChrysCapital's Sanjay Kukreja

The common thread is backing grounded founders who are hands-on and have a relentless focus on execution

Zydus Life up 3% on mixed Q3, mcap tops Rs 1 trn; analysts split on outlook

Despite challenges from a lower-margin product mix, Zydus Life benefitted from forex gains and a favourable tax rate, which led to a PAT beat, analysts said

Abbott India share rises 3% as JPMorgan ups target to Rs 31,500; details

The surge in Abbott India share price followed reports that JPMorgan, a New York-based financial services firm, raised its target price to Rs 31,500, up from Rs 30,000, signaling an upside of 12%